201 related articles for article (PubMed ID: 23190892)
1. Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.
Jenkins NC; Jung J; Liu T; Wilde M; Holmen SL; Grossman D
J Invest Dermatol; 2013 Apr; 133(4):1043-51. PubMed ID: 23190892
[TBL] [Abstract][Full Text] [Related]
2. The p16(INK4A) tumor suppressor regulates cellular oxidative stress.
Jenkins NC; Liu T; Cassidy P; Leachman SA; Boucher KM; Goodson AG; Samadashwily G; Grossman D
Oncogene; 2011 Jan; 30(3):265-74. PubMed ID: 20838381
[TBL] [Abstract][Full Text] [Related]
3. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
[TBL] [Abstract][Full Text] [Related]
4. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Zhang B; Peng ZY
Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
[TBL] [Abstract][Full Text] [Related]
5. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
6. A novel CDKN2A variant (p16
Li C; Liu T; Liu B; Hernandez R; Facelli JC; Grossman D
Pigment Cell Melanoma Res; 2019 Sep; 32(5):734-738. PubMed ID: 31001908
[TBL] [Abstract][Full Text] [Related]
7. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
8. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
9. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
10. Absence of AMPKα2 accelerates cellular senescence via p16 induction in mouse embryonic fibroblasts.
Ding Y; Chen J; Okon IS; Zou MH; Song P
Int J Biochem Cell Biol; 2016 Feb; 71():72-80. PubMed ID: 26718972
[TBL] [Abstract][Full Text] [Related]
11. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.
Fan M; Pfeffer SR; Lynch HT; Cassidy P; Leachman S; Pfeffer LM; Kopelovich L
Oncotarget; 2013 Jan; 4(1):128-41. PubMed ID: 23371019
[TBL] [Abstract][Full Text] [Related]
12. The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation.
Piepkorn M
J Am Acad Dermatol; 2000 May; 42(5 Pt 1):741-5. PubMed ID: 10775848
[TBL] [Abstract][Full Text] [Related]
13. Molecular regulation of melanocyte senescence.
Bennett DC; Medrano EE
Pigment Cell Res; 2002 Aug; 15(4):242-50. PubMed ID: 12100489
[TBL] [Abstract][Full Text] [Related]
14. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.
Jonsson A; Tuominen R; Grafström E; Hansson J; Egyhazi S
J Invest Dermatol; 2010 Dec; 130(12):2809-17. PubMed ID: 20703244
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.
Rizos H; Darmanian AP; Holland EA; Mann GJ; Kefford RF
J Biol Chem; 2001 Nov; 276(44):41424-34. PubMed ID: 11518711
[TBL] [Abstract][Full Text] [Related]
17. p16(Ink4a) in melanocyte senescence and differentiation.
Sviderskaya EV; Hill SP; Evans-Whipp TJ; Chin L; Orlow SJ; Easty DJ; Cheong SC; Beach D; DePinho RA; Bennett DC
J Natl Cancer Inst; 2002 Mar; 94(6):446-54. PubMed ID: 11904317
[TBL] [Abstract][Full Text] [Related]
18. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species promotes cellular senescence in normal human epidermal keratinocytes through epigenetic regulation of p16(INK4a.).
Sasaki M; Kajiya H; Ozeki S; Okabe K; Ikebe T
Biochem Biophys Res Commun; 2014 Sep; 452(3):622-8. PubMed ID: 25181340
[TBL] [Abstract][Full Text] [Related]
20. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
Parry D; Peters G
Mol Cell Biol; 1996 Jul; 16(7):3844-52. PubMed ID: 8668202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
